Company: ARWR
Filing Date: 2025-09-12
Form Type: 8-K
Source: 0000879407-25-000010
Chunk: 0

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-09-12
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events

Arrowhead Pharmaceuticals, Inc. (the “ Company”) was notified that on September 11, 2025, Ionis Pharmaceuticals, Inc. (“ Ionis”) filed a Complaint for Patent Infringement against the Company in the United States District Court for the Central District of California alleging patent infringement of United States Patent No. 9,593,333 (“the ’333 patent”). As the Company previously reported, on September 10, 2025, the Company filed a Complaint for Declaratory Judgment in the United States District Court for the District of Delaware against Ionis to declare that the ’333 patent is invalid and not infringed by the Company’s planned commercialization of investigational plozasiran. A copy of Ionis’s complaint is attached hereto as Exhibit 99.1 (the “ Complaint”).

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this report except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. These forward-looking statements include, but are not limited to, statements about our planned commercialization of investigational plozasiran and beliefs and expectations regarding the Company’s claims and lawsuits against Ionis and the validity and enforceability of the ‘333 Patent. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results or outcomes may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

  Exhibit No.      Description                                                                                           
 ─────────────────────────────────────────────────────────────────────────────────